Stockscreener 앱 받기
72.02
0.41%
-0.42
전일 마감가:
$72.44
열려 있는:
$72.5
하루 거래량:
291.07K
Relative Volume:
0.05
시가총액:
$216.81B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
28.92
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
+3.16%
1개월 성능:
+5.38%
6개월 성능:
+8.86%
1년 성능:
-5.51%
1일 변동 폭
$72.05
$72.52
1주일 범위
$69.70
$72.67
52주 변동 폭
$61.24
$87.67
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
72.06 | 216.81B | 54.98B | 7.77B | 9.14B | 2.49 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
Cytokinetics reveals unexpected delay; AstraZeneca combo therapy hits in asthma - BioPharma Dive
AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma - Yahoo Finance
AstraZeneca reports success in phase III asthma trials By Investing.com - Investing.com India
AstraZeneca reports success in phase III asthma trials - Investing.com
AstraZeneca's 'smoker's lung' therapy meets main goals of late-stage asthma trials - Reuters
AstraZeneca (AZN) Achieves Major Milestones in Asthma Treatment Trials - GuruFocus
AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials - insights.citeline.com
AstraZeneca's (AZN) Breztri Aerosphere Achieves Key Milestones i - GuruFocus
AstraZeneca posts phase 3 win for asthma drug (AZN:NASDAQ) - Seeking Alpha
AstraZeneca’s asthma therapy shows promise in trials By Investing.com - Investing.com UK
AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials - GuruFocus
AstraZeneca (AZN) Triple Therapy Shows Promise in Asthma Trials | AZN Stock News - GuruFocus
AstraZeneca’s share price is down 20% from September, so is it time for me to buy? - MSN
AstraZeneca's Asthma Drug Improves Lung Function in Late-stage Studies - marketscreener.com
AstraZeneca Plc Breztri succeeds in Phase III asthma trials - DirectorsTalk Interviews
AstraZeneca's Breztri meets main goals of late-stage asthma trials - marketscreener.com
AstraZeneca and AI startup join forces in the fight against lung cancer - Mugglehead Magazine
AstraZeneca Director Buys ADSs Worth Over $100,000 - Investing.com
AstraZeneca reports total voting rights - Investing.com
AstraZeneca quietly exits neuroscience - BioPharma Dive
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - Benzinga
AstraZeneca (AZN) Reports Strong Q1 Earnings and Reiterates Guid - GuruFocus
Up 7.5% in a week! Is the GSK share price about to do an AstraZeneca? - Yahoo
AstraZeneca Faces Intensified Probe in China as Tax Evasion Amount Grows - Caixin Global
Imfinzi approval positions AstraZeneca at forefront of perioperative MIBC - Clinical Trials Arena
AstraZeneca (AZN) Contemplates U.S. Production Expansion Amid Ta - GuruFocus
AstraZeneca PLC (NASDAQ:AZN) Q1 2025 Earnings Call Transcript - Insider Monkey
AstraZeneca has plenty coming down the pipeline to appease the bears - Proactive Investors
AstraZeneca’s Truqap fails in another Phase III trial - Yahoo Finance
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... - Yahoo Finance
AstraZeneca - Britannica
AstraZeneca PLC (AZN) Q1 2025 Earnings Call Highlights: Strong R - GuruFocus
PRESS DIGEST-British BusinessApril 30 - marketscreener.com
BofA Securities Keeps AstraZeneca at Buy as Q1 EPS Tops Consensus - marketscreener.com
AstraZeneca’s Calquence gets CHMP nod for CLL in the EU By Investing.com - Investing.com India
Press Release Distribution & PR Platform - ACCESS Newswire
EU panel backs AstraZeneca’s Calquence for CLL treatment - Investing.com
AstraZeneca’s Calquence gets CHMP nod for CLL in the EU - Investing.com
AstraZeneca halts phase III trial of prostate cancer drug By Investing.com - Investing.com India
AstraZeneca halts phase III trial of prostate cancer drug - Investing.com
AstraZeneca CEO calls for increased European investment in pharma - Pharmaceutical Technology
AstraZeneca Loses IP Shield For Diabetes Drug - Law360
Astrazeneca Does not Expect Material Long-Term Impact From US Tariffs, CEO Says - marketscreener.com
AstraZeneca (AZN) Q1 2025 Earnings Highlight 10% Revenue Growth - GuruFocus
AstraZeneca shares claw their way back into green after revenue miss - Proactive Investors
AstraZeneca CEO: Trump tariffs 'not material long term' - Yahoo Finance
AstraZeneca says potential US tariffs manageable, faces another China fine - marketscreener.com
AstraZeneca (AZN) Stock: Strong Q125 Growth Bolsters Path to $80B Revenue Goal - CoinCentral
FTSE 100 makes late surge after AstraZeneca, BP and AB Foods setbacks - Proactive Investors
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):